On July 2, the American Society of Nephrology (ASN) and the National Kidney Foundation (NKF) released a joint statement announcing the establishment of a joint task force that aims to reassess the includsion of race in diagnosing kidney diseases.
"Of the more than 37 million people affected by kidney diseases in the United States, a disproportionate number are of African American, Hispanic, Asian, and Native American descent. African Americans are three times more likely than Non-Hispanic Whites to experience kidney failure. Such disparities go beyond the high prevalence of kidney diseases and extend into differences in treatment modality, including access to transplantation. While African Americans represent 35% of people receiving dialysis in the United States, they are less likely to be identified as kidney transplant candidates when compared to Non-Hispanic White," begins the statment.
On July 2, the American Society of Nephrology (ASN) and the National Kidney Foundation (NKF) released a joint statement announcing the establishment of a joint task force that aims to reassess the includsion of race in diagnosing kidney diseases.
"Of the more than 37 million people affected by kidney diseases in the United States, a disproportionate number are of African American, Hispanic, Asian, and Native American descent. African Americans are three times more likely than Non-Hispanic Whites to experience kidney failure. Such disparities go beyond the high prevalence of kidney diseases and extend into differences in treatment modality, including access to transplantation. While African Americans represent 35% of people receiving dialysis in the United States, they are less likely to be identified as kidney transplant candidates when compared to Non-Hispanic White," begins the statment.
The statement confirms, "NKF and ASN are forming a joint task force to examine the inclusion of race in the estimation of GFR and its implications for the diagnosis and subsequent management of patients with, or at risk for, kidney diseases. This task force will issue its initial recommendations in 2020. It is important that any change in eGFR reporting carefully consider the multiple social and clinical implications, be based on rigorous science, and be part of a national conversation about uniform reporting of eGFR across health care systems. The task force will keep laboratories, clinicians, and other kidney health professionals apprised of any potential long-term implications of removing race from the eGFR formula."
For more information please see the full statement .
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory